MannKind Corporation (MNKD)
Market Cap | 1.36B |
Revenue (ttm) | 76.23M |
Net Income (ttm) | -97.51M |
Shares Out | 263.20M |
EPS (ttm) | -0.38 |
PE Ratio | n/a |
Forward PE | 303.03 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,369,967 |
Open | 5.20 |
Previous Close | 5.29 |
Day's Range | 5.15 - 5.33 |
52-Week Range | 2.49 - 5.51 |
Beta | 1.67 |
Analysts | Buy |
Price Target | 6.22 (+20.08%) |
Earnings Date | Feb 23, 2023 |
About MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NR... [Read more]
Financial Performance
In 2021, MannKind's revenue was $75.44 million, an increase of 15.81% compared to the previous year's $65.14 million. Losses were -$80.93 million, 41.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for MNKD stock is "Buy." The 12-month stock price forecast is $6.22, which is an increase of 20.08% from the latest price.
News

MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic pr...

MannKind's Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic pr...

MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of innovative therapeutic ...

After Golden Cross, MannKind (MNKD)'s Technical Outlook is Bright
Is it a good or bad thing when a stock experiences a golden cross technical event?

MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting
WESTLAKE VILLAGE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices ...

MannKind (MNKD) Reports Q3 Loss, Tops Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of 40% and 35.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MannKind Corporation Reports 2022 Third Quarter Financial Results
Conference Call to Begin Today at 9:00 a.m. (ET) Conference Call to Begin Today at 9:00 a.m. (ET)

MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 third quarter and year to date financial results and its manage...

7 Penny Sleeper Stocks to Buy Before Wall Street Wakes Up
Penny sleeper stocks can offer tremendous risks to investors. However, much like any other speculative investment category, it's possible that traders can still generate incredible, perhaps life chang...

MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeuti...

7 Penny Stocks That Actually Have a Buy Rating
Finding penny stocks with buy ratings is becoming increasingly difficult. The higher interest rates go, the more risk-averse the markets become.

Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic p...

MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeuti...

MannKind (MNKD) Reports Q2 Loss, Tops Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of -22.22% and 15.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MannKind Corporation Reports 2022 Second Quarter Financial Results
Conference Call to Begin Today at 5:00 p.m. (ET)

MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 second quarter and year to date financial results and its manag...

MannKind Corporation to Participate in the BTIG Biotechnology Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic...

Mannkind to Host Product Theater and Booth at the American Diabetes Association's 82nd Scientific Sessions in New Orleans, June 3-7
WESTLAKE VILLAGE, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patie...

MannKind's Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic ...

MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic pro...

MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of therapeutic products fo...

MannKind Corporation Participating at Upcoming Conferences
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic pro...

MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of 0% and 14.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MannKind Corporation Reports 2022 First Quarter Financial Results
Conference Call to Begin Today at 5:00 p.m. (ET) Conference Call to Begin Today at 5:00 p.m. (ET)